Starting a GLP-1: questions to ask before the first dose
Before your first dose, bring your health history, current medicines, and goals to your clinician, then confirm the exact product, how and when it is taken, how follow-up works, what it costs, and whom to call. Your prescriber decides whether a GLP-1 medicine is suitable. The product’s label and Medication Guide are the source for instructions.
Quick answer
Before your first dose, bring your health history, current medicines, and goals to your clinician, then confirm the exact product, how and when it is taken, how follow-up works, what it costs, and whom to call. Your prescriber decides whether a GLP-1 medicine is suitable. The product’s label and Medication Guide are the source for instructions.
Share your health context
Tell the prescriber about:
- Conditions. Personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication for Wegovy. Also mention pancreatitis, gallbladder disease, kidney disease, diabetes, and diabetic eye disease; the label has warnings for each. Source: Wegovy label sections 4 and 5.
- Diabetes medicines. The label says to monitor blood glucose in people with diabetes, and notes hypoglycemia (low blood sugar) can occur.
- Pregnancy plans. The label says Wegovy may cause fetal harm and advises stopping at least 2 months before a planned pregnancy for weight-reduction use (section 8).
- Pancreas or kidney problems, and diabetic retinopathy. The Medication Guide asks you to tell your provider about these, and about breastfeeding.
- Planned surgery or procedures. GLP-1 medicines slow stomach emptying, and rare cases of aspiration during anesthesia have been reported. The label says to tell your care team before any procedure (section 5.10).
- Other medicines and supplements including any other GLP-1 or semaglutide product. The label does not recommend combining them.
Label note: Table 3 reports vomiting in 24% of Wegovy injection recipients; the gastrointestinal-reactions narrative in section 6.1 reports 25%. This is a difference within the label, not two separate comparison trials. The figure follows Table 3.
Agree on the plan
- Which exact product, strength and form (weekly injection or daily tablet)? Products are not interchangeable. Instructions differ.
- How will the prescriber adjust the dose over time? The label describes gradual dose increases to reduce stomach side effects. Your prescriber sets your plan.
- What side effects should I expect, and which need a call? See the chart below and the Medication Guide.
- What follow-up and monitoring is planned? Ask when you will check in, and what to track.
- What will it cost each month, and what if coverage changes? For a practical checklist, read questions behind the monthly treatment price.
- Who do I contact for questions or urgent symptoms? Get a name and a number before dose one.
What to expect: side effects reported in trials

Common adverse reactions in Wegovy trials
In the label’s trials of adults with obesity or overweight, nausea was reported by 44% of people on Wegovy injection versus 16% on placebo, and diarrhea by 30% versus 16%. Other common reports included vomiting, constipation, abdominal pain, headache and fatigue. The label says gastrointestinal reactions were most often reported during dose escalation. Overall, 6.8% of people on Wegovy 2.4 mg and 3.2% on placebo permanently stopped treatment because of adverse reactions. These are group results from trials, not a forecast for any one person. Source: Wegovy label sections 6.1 and Table 3.
Before dose one
- Read the Wegovy Medication Guide and instructions for use that come with your exact product. Ask your pharmacist or clinician to walk you through them.
- Ask your clinician which symptoms to report and how. The Medication Guide lists symptoms that call for stopping the medicine and calling right away, such as severe abdominal pain that will not go away. For a tracking checklist to discuss with your care team, read side effects after a dose increase.
- If any part of the product arrives damaged, warm, or different from what was prescribed, contact the pharmacy before using it.
What this does not establish
This page does not say who should or should not take a GLP-1 medicine. It is not a complete list of warnings. Labels change, so the current label for your product controls.
FAQs
What should I discuss with my clinician about starting a GLP-1? Your history, medicines, pregnancy plans, upcoming procedures, goals, the exact product and schedule, follow-up, cost, and who to call.
What information should I bring? A list of medicines and supplements, past treatments, relevant conditions, and your questions.
Where can I find instructions for my exact medicine? Use its label and Medication Guide, and the written instructions from your pharmacy. Ask your pharmacist or clinician if they conflict or are unclear.
Sources
Source methods and reading limits
Sources checked against Europe PMC abstracts and product-label text: November 17, 2026. Full text was not read for abstract-only claims. Source dates and reading limits are recorded with the supporting references.